TerrAscend Corp. · TSX:TSND

TerrAscend — Investor Presentation (October 2019)

19 slides from TerrAscend's investor presentation, October 2019

  1. Slide 1: TerrAscend Investor Presentation October 2019

    www.terrascend.com O C T O B E R 2 019

  2. Slide 2: Disclaimer and forward-looking information

    Investors and prospective investors should rely only on the information contained in the disclosure filings (the “Filings”) of TerrAscend Corp. (the “Company”). This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in Filings.

  3. Slide 3: US$57.8B total addressable market

    (Market values in USD) 2018 2024E $11.0B 24.4% CAGR $40.6B United States $0.6B 44.4% CAGR $5.2B US$57.8B Total addressable market Canada opportunity that TerrAscend is well positioned to capture with access to three of the $0.3B 83.2% CAGR $12.0B world’s largest markets for cannabis European Union(1

  4. Slide 4: Key Metrics and Investment Highlights

    Key Metrics(1) Investment Highlights A global cannabinoid company, committed to scientific innovation and operational integrity 500+ 10,000+ Store Distribution Employees Network for CBD Access to three of the world’s largest cannabinoid markets with strong foothold in the U.S. and Canada, as well as

  5. Slide 5: Growing U.S. Footprint and Canadian Operations with Global Distribution

    Growing U.S. Footprint with Selective Vertical Integration Canadian Operations with Platform for Global Distribution CA NV PA NJ Nationwide TerrAscend has 1 of only 11 facilities in the Cultivation Cultivation Cultivation Cultivation world with an EU-Good Manufacturing Distribution Practices (EU-GMP

  6. Slide 6: Management team

    Dr. Michael Nashat Matthew J. Johnson Adam Kozak Joanna Halligan Heather Molloy Brian Feldman CEO, Co-Founder & President Chief Financial Officer VP, Human Resources EVP, Business General Counsel Director Development 12+ years of experience in 25+ years of experience in 20+ years of experience in 13

  7. Slide 7: Board of directors

    Jason Wild Richard Mavrinac Chairman Director o President and Chief Investment Officer of JW Asset Management, which o Served as CFO for George Weston Limited and Executive VP of he founded in 1998. The company has a strong track record in finding Loblaw Companies and developing opportunities within

  8. Slide 8: Team brings strong, diversified pedigree with deep expertise

    Team brings strong, diversified pedigree with deep expertise O UR PA RTNER S OUR EXPERIENCE PRIVATE & CONFIDENTIAL SEPTEMBER OCTOBER A P R I L 2 02019 12019 9 p.p.8 8

  9. Slide 9: Four-pronged business model overview

    Canadian Licensed Producer (LP) U.S. Multi-State Operator (MSO) with Global Distribution o Acquired The Apothecarium and Ilera Healthcare to o Canadian LP with a 67,300 sq. ft. cultivation and serve as foundations of vertically integrated U.S. processing facility operations o Wholesale supply agreem

  10. Slide 10: Providing quality, pharmaceutical-grade products to 25M people

    Providing quality, pharmaceutical-grade products to 25M people o 67,300 sq. ft. production and manufacturing facility – Licensed production area of 51,800 sq. ft. – Substantial capacity to manufacture and package quality cannabinoid products for medical and adult-use consumers o Products available t

  11. Slide 11: Unmatched scientific capabilities in the cannabis industry

    TerrAscend is creating unmatched scientific capabilities in the cannabis industry Ascendant Laboratories Solace Rx o Cannabis biotechnology and o The industry’s first Drug Preparation licensing company committed to the Premises (DPP) facility will allow continuous improvement of the TerrAscend to in

  12. Slide 12: The Apothecarium dispensaries

    Named the best-designed dispensary in the country by Architectural Digest Three retail stores in California and one retail store in Nevada generated ~US$45M revenue in 2018 Awarded regulatory approval in February for fifth location in Berkeley, CA on high-foot traffic Telegraph Avenue. Construction

  13. Slide 13: Hemp-derived CBD brand

    o 50+ SKUs, including tinctures, o 15+ SKUs, including formulated edibles, and vapes gel caps and tinctures o Strong recognition with Gen X o Universal appeal across and young adults p customer segments . o Significant traction in 1 o Expansion into natural foods convenience stores, smoke 3 as well

  14. Slide 14: Ilera Healthcare Pennsylvania facility

    o State-of-the-art greenhouse designed for optimal plant growth o Cultivation and processing facility with a genetic library of over 170 cannabis strains 67,000 sq. ft. facility operating at full capacity with an o Significant market share in Pennsylvania’s limited license market expansion to 127,00

  15. Slide 15: New Jersey limited license market

    A limited license market with recreational legalization on the horizon o First-mover advantage in establishing New Jersey footprint 16-acre site with up to 200,000 sq. ft. of cultivation – Per State regulators, TerrAscend has progressed the furthest and processing, with 80,000 sq. ft. in initial pha

  16. Slide 16: Bringing our best brands and formulations into thousands of retail channels

    Bringing our best brands and formulations into thousands of retail channels Founded in quality and the Knüba is committed to A boutique brand with a High-quality, handcrafted Flavorful and affordable Unique formulas pairing Formulations designed with pursuit of innovation, Haven simplifying choices

  17. Slide 17: Significant opportunities and M&A transactions to date

    Significant Opportunities for… M&A Transactions to Date o Geographic expansion and diversification Company Geography Overview Transaction Value(1) Status (USD) o Accelerated market access for brands and formulations of both TerrAscend and (2) Industry leader in the production Nationwide target compa

  18. Slide 18: Revenue growth driven by M&A strategy and organic initiatives

    Revenue growth driven by execution of M&A strategy and organic initiatives Legend Reported Revenue Pro Forma Revenue(1) $50 Over 2,200% $45 Growth Shareholders approved U.S. $42.2 expansion to pursue growth Nov. 27, 2018 $40 opportunities including $37.3 strategic acquisitions $35 ($ in millions) $3

  19. Slide 19: SEPTEMBER 2019

    SEPTEMBER 2019 p.19

TerrAscend — Investor Presentation (October 2019) on 6ix